Top Quality Companies To Watch In Right Now

New York City is an odd place, home to financiers who earn more per month than ordinary folks will in a lifetime, but deep poverty as well. People gawk at the high cost of living in New York, but the city's median household income is actually below the national average. The gap between New York's rich and its average is off the charts.

It's against this backdrop that I visited economist Joseph Stiglitz at his office in Columbia Business School in early April to talk about his favorite subject: wealth inequality.

Stiglitz won the Nobel Prize in economics in 2001 for his work on information asymmetries. But it's his commentary on wealth inequality that has gained the most attention from admirers and critics. An article Stiglitz penned for Vanity Fair in May 2011 titled "Of the 1%, by the 1%, for the 1%" set off a wave of discussion about the nation's growing chasm of wealth, and helped spawn the Occupy Wall Street movement. TIME magazine named him one of the 100 most influential people in the world that year.

5 Best Consumer Service Stocks To Buy For 2015: SOHM Inc (SHMN)

SOHM, Inc. is a global generic pharmaceutical manufacturer, developer and marketer having a range of products, covering the therapeutic segments. The Company has its presence in healthcare segments, such as nutraceuticals, dermatology and all other therapeutic segments.

The Company�� generic pharmaceuticals are exported globally with a focus on distribution in Africa, Latin America and Southeast Asia. The Company�� products has presence in analgesic, anti-flammatory, drops, suspensions, vitamins and tonics, antibiotics, beta-lactum antibiotics, injections, syrups, anti-cold, capsules, nutraceutical and tablets.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks VizStar Inc (OTCMKTS: VIZS), SOHM Inc (OTCMKTS: SHMN) and American Soil Technologies, Inc (OTCMKTS: SOYL) have been getting some attention in various investment newsletters with two out of three of these stocks being the subject of paid promotions. However, there is nothing wrong with some paid for attention so long as everything is properly disclosed, but its going to be up to investors and traders alike to ultimately decide whether any of these stocks have what it takes to be the next hot stock. With that in mind, here is a quick reality check about all three small cap stocks:

Top Quality Companies To Watch In Right Now: Medbox Inc (MDBX.PK)

Medbox Inc. (Medbox) offers a machine that dispenses medication to individuals based on biometric identification (fingerprint sample). The machine allows pharmacies, hospitals, doctors' offices, and alternative medicine clinics to manage employee possession of sensitive drugs. The system also allows these clinics to demonstrate that the user visiting the machine is a registered patient and that the patient has a valid and unexpired authorization from a physician to possess and use the medicine dispensed. The Company has national and international presence with offices in Los Angeles, New York, Toronto, London and Tokyo.

Medbox, through its subsidiaries, offers consulting services to the alternative medicine industry, as well as to the mini self-storage market. The Company provides consulting services primarily to individuals and groups seeking to establish new clinics and facilities, often in jurisdictions that have recently passed legislation concerning th e availability of alternative medicines, as well as existing jurisdictions, nationwide.

Advisors' Opinion:

• [By Alan Brochstein]

  Taking into account all of the data I have shared, I want to introduce my take on the most important names to follow. My initial list takes into account not only the market cap, but also business model and interest level. These are the stocks that I think merit the most attention (in alphabetical order):

  CannaVest (CANV.OB)GW Pharma (GWPH)MedBox (MDBX.PK)Medical Marijuana, Inc. (MJNA.PK)

  CANV doesn't really trade, as it is held closely by insiders (99.7%, including MJNA). I have a few concerns, including the valuation and some near-term financial challenges typical of a start-up with just one client looking to expand its customer base, but I like the focus and the fact that it is an SEC filer with a relatively clean history (i.e. none of the baggage of some of these other companies). I have spoken to its outsourced CFO and am impressed by his background (has been CFO or held key financial roles at publicly-traded healthcare companies). CANV is the partner to MJNA that is responsible for manufacturing the CBD (Cannibidiol, the cannabinoid in marijuana that is increasingly viewed as offering substantial medical benefits). I am very concerned about the near-term financials, but this is a pure-play with probably a two-year lead over other companies. I don't see a moat in terms of intellectual property or brands, but they have a good lead in terms of sourcing of supply and penetration into potential customers. Quite simply, they don't appear to have competition at present. The company, then, is a call option on CBD demand taking off. It appears that it could be a supplier to even Big Pharma should medical marijuana research move into the mainstream.

Top Quality Companies To Watch In Right Now: Titan Pharmaceuticals Inc (TTNP)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By CRWE]

  Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).

  Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.

Top Quality Companies To Watch In Right Now: Connecticut Water Service Inc. (CTWS)

Connecticut Water Service, Inc., through its subsidiaries, operates as a regulated water company in Connecticut. It operates in three segments: Water Activities, Real Estate Transactions, and Services and Rentals. The Water Activities segment supplies drinking water. The Real Estate Transactions segment involves in the sale or donation of its real estate holdings. The Services and Rentals segment provides contracted services to water and wastewater utilities and other clients, which include contract operations of water and wastewater facilities; Linebacker, an optional service line protection program that comprises repairing or replacing leaking or broken water service line, curb box, curb box cover, meter pit, meter pit cover, meter pit valve, and in-home water main shut off valve before the meter; and providing bulk deliveries of emergency drinking water to businesses and residences through tanker trucks. This segment also engages in leasing and renting residential and c ommercial properties. As of December 31, 2009, Connecticut Water Service, Inc. served 88,534 customers in 54 towns in Connecticut. The company was founded in 1956 and is headquartered in Clinton, Connecticut.

Advisors' Opinion:

• [By David Dittman]

  Answer: Our favorite water utilities–American Water Works, Aqua America Inc (NYSE: WTR), Connecticut Water Service Inc (NSDQ: CTWS)–are solid dividend growers throughout the cycle, and they all have pretty good growth prospects because of the abundance of small-scale municipal water utilities in their footprints.

Top Quality Companies To Watch In Right Now: Watson Pharmaceuticals Inc.(WPI)

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. The company offers its products for therapeutic categories, such as central nervous system, cardiovascular, hormones and synthetic substitutes, anti-infective agents, and urology. It operates in three segments: Global Generics, Global Brands, and Distribution. The Global Generics segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties? brand products. This segment offers various dosage forms, such as oral solids, transdermals, injectables, inhalation products, and transmucosals for indications, including pregnancy prevention, pain management, depression, hypertension, and smoking cessation. The Global Brands segment pr omotes and co-promotes Rapaflo, Gelnique, Trelstar, Androderm, Crinone, ella, INFeD, Generess, sodium ferric gluconate, AndroGel, and Femring branded products; and markets its products through sales professionals. It also sells various non-promoted products. The Distribution segment distributes generic and select brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians? offices. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. Watson Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Parsippany, New Jersey.

Advisors' Opinion:

• [By Louis Navellier]

  Actavis Plc is one of the world’s largest generic drugmakers. For the past three decades, this company was known as Watson Pharmaceuticals (WPI), but the company rebranded itself as Actavis in 2013. With a portfolio of over 190 pharmaceutical product families, Actavis has its name on everything from antibiotics to contraceptives to smoking cessation treatments.

Top Quality Companies To Watch In Right Now: Paychex Inc.(PAYX)

Paychex Inc., together with its subsidiaries, provides payroll, human resource, and benefits outsourcing solutions for small-to medium-sized businesses in the United States and Germany. It offers payroll processing services, including calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and management reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients? payroll obligations. The company also provides payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. Its human resource outsourcing services include payroll, employer compliance, human resource and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained human resource representative, as well as provides employee handbooks, management manuals, and r equired regulatory forms. In addition, the company offers retirement services administration; workers? compensation; business-owner policies; commercial auto; and health and benefits coverage, including health, dental, vision, and life. Further, it provides online human resource administration software products for employee benefits management and administration, and time and attendance solutions. As of May 31, 2010, the company served approximately 536,000 clients in the United States; and 1,700 clients in Germany. Paychex, Inc. was founded in 1971 and is headquartered in Rochester, New York.

Advisors' Opinion:

• [By Alyssa Oursler]

  But a few dreamy stocks have have provided double rewards for loyal shareholders so far in 2013.�Texas Instruments�(TXN),�Seagate Technology�(STX),�Paychex�(PAYX),�Lockheed Martin�(LMT) and Blackstone Group (BX) are five dividend stocks that have been anything but sleepy so far this year.

• [By Morgan Housel]

  Martin Mucci, CEO, Paychex (NASDAQ: PAYX  ) :

  I think when you look at some of the economic indicators, housing starts are up, prices are up on housing. I think housing is a really important measure for us because we have a lot of jobs around that. A lot of contracting roofers, et cetera, around that. All of that is positive. And so we're feeling like we're coming off the end of the year with some momentum, and that will certainly help us.

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  Paychex Inc.(PAYX) said its fiscal third-quarter earnings rose 11% as the company reported higher revenue in both its payroll and human resource services businesses. Shares edged up 3.2% to $43.25 premarket.

• [By Chris Hill]

  In this installment, Jason and Matt explain why they're keeping a close watch on shares of Paychex (NASDAQ: PAYX  ) and Nike (NYSE: NKE  ) .